Efficacy and safety of c-type natriuretic peptide analogues in children with achondroplasia: A systematic review and meta-analysis of randomised clinical trials
Article History
-
Received: ,
Accepted: ,
,
Abstract
Objectives:
Achondroplasia is a genetic skeletal disorder characterised by impaired endochondral ossification and disproportionate short stature. C-type natriuretic peptide (CNP) analogues have emerged as targeted therapies to improve growth outcomes; however, comparative evidence across agents remains limited.
Material and Methods:
A systematic review and meta-analysis of randomised controlled trials (RCTs) was conducted to evaluate the efficacy and safety of CNP-based therapies in children with achondroplasia. The primary outcome was annualised growth velocity (AGV) at 52 weeks. Secondary outcomes included height Z-score, upper-to-lower body segment ratio and safety outcomes. Random-effects models with Hartung–Knapp adjustment were applied, and an exploratory network meta-analysis (NMA) was performed.
Results:
Four RCTs were included. CNP-based therapies significantly improved AGV compared with placebo (mean difference [MD] = 1.39 cm/year; 95% confidence interval [CI]: 0.89–1.90). Height Z-score also improved (MD = 0.28; 95% CI: 0.24–0.33), while no significant change was observed in body proportionality. There was no significant difference in safety outcomes; however, injection-site reactions were more frequent. NMA showed that both vosoritide and navepegritide were superior to placebo, with no significant difference between agents.
Conclusion:
CNP-based therapies improve growth outcomes with an acceptable safety profile and should be integrated into multidisciplinary care. Further head-to-head studies are needed.
Keywords
How to cite this article: Kumar B, Bharghavi SRB, Sanjeev I, Ranjan Meher B. Efficacy and safety of c-type natriuretic peptide analogues in children with achondroplasia: A systematic review and meta-analysis of randomised clinical trials. Karnataka Paediatr J. doi: 10.25259/KPJ_70_2026
INTRODUCTION
Achondroplasia is the most prevalent genetic skeletal dysplasia, with an estimated prevalence of 1 in 20,000 to 30,000 live births. It is caused by a gain-of-function mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, which negatively regulates endochondral ossification.[1,2] This mutation impairs chondrocyte proliferation and differentiation at the growth plate, resulting in disproportionate short stature and characteristic skeletal features.[3] Achondroplasia is now increasingly recognised as a multisystem disorder, with affected individuals experiencing complications such as foramen magnum stenosis, spinal canal narrowing, obstructive sleep apnoea, recurrent otitis media and orthopaedic deformities.[4-6] These complications contribute to increased morbidity, functional impairment and reduced quality of life throughout the lifespan.[4,7] Recent international consensus guidelines emphasise the need for lifelong multidisciplinary management, including regular surveillance and early intervention for associated complications.[6]
Historically, treatment strategies for achondroplasia have primarily focused on managing complications rather than the underlying disease mechanism. Supportive care consists of neurosurgical decompression for foramen magnum stenosis, orthopaedic interventions for limb deformities and management of respiratory and otologic complications. Growth-promoting interventions, such as recombinant human growth hormone, have been investigated; however, their impact on final height remains modest and inconsistent.[8] Limb-lengthening procedures may increase stature but are associated with considerable morbidity, extended treatment duration and ethical concerns.[9] These challenges underscore the necessity for disease-modifying therapies that directly target the molecular basis of achondroplasia.
Recent advances in the understanding of FGFR3 signalling have facilitated the development of targeted therapies, with C-type natriuretic peptide (CNP)-based treatments representing a promising strategy.[10] CNP functions as a positive regulator of endochondral bone growth by binding to natriuretic peptide receptor-B and inhibiting the mitogen-activated protein kinase pathway downstream of FGFR3, which promotes chondrocyte proliferation and differentiation.[11] Vosoritide, a CNP analogue administered as a once-daily subcutaneous injection, has demonstrated significant improvements in annualised growth velocity (AGV) among children with achondroplasia in randomised controlled trials (RCTs).[12] Subsequent studies have confirmed both sustained efficacy and an acceptable safety profile with long-term use.[13] More recently, navepegritide (TransCon CNP), a long-acting prodrug intended for once-weekly administration, has been developed to provide sustained CNP exposure while reducing peak-related adverse effects.[14] Clinical trials of navepegritide have reported improvements in growth velocity and a favourable safety profile, including low rates of injection-site reactions and no clinically significant hypotension.[15]
Despite these promising findings, the current evidence base for CNP-based therapies is limited to a small number of RCTs, which exhibit heterogeneity in study populations, dosing regimens and follow-up durations. Furthermore, differences between daily and long-acting formulations, as well as variability in reported outcomes, complicate the interpretation of the overall magnitude and consistency of treatment effects across studies. A comprehensive synthesis of the available evidence is required to more accurately characterise the efficacy and safety profiles of these therapies. To address this research gap, we conducted a systematic review and meta-analysis of RCTs to evaluate the efficacy and safety of CNP analogues compared with placebo in children with achondroplasia.
MATERIAL AND METHODS
Development and registration of protocol
The protocol for this systematic review and meta-analysis was prospectively registered in the International Prospective Register of Systematic Reviews under registration number CRD420261343782. Protocol development adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2020 guidelines.[16] Study conduct and reporting followed the recommendations of the PRISMA 2020 statement.[17] The Cochrane Handbook for Systematic Reviews of Interventions provided methodological guidance throughout the review process. The completed PRISMA 2020 checklist is available in Supplementary Table S1.
Search strategy
A comprehensive and systematic literature search was independently conducted by two reviewers across MEDLINE/PubMed, Embase, the Cochrane Database and the World Health Organization International Clinical Trials Registry Platform to identify RCTs assessing the efficacy and safety of CNP-based therapies in achondroplasia. The search covered all records from database inception to February 2026, with no restrictions on language or publication year. The search strategy was structured using the Population, Intervention, Comparison, Outcome framework and incorporated relevant medical subject headings, Emtree terms and free-text keywords, combined with Boolean operators ‘AND’ and ‘OR’. The primary search terms included ‘Achondroplasia’ AND (‘vosoritide’ OR ‘navepegritide’ OR ‘TransCon CNP’ OR ‘C-type natriuretic peptide’ OR ‘CNP’) AND (‘growth velocity’ OR ‘annualised growth velocity’ OR ‘AGV’ OR ‘height’ OR ‘height SDS’). The search syntax was adapted for each database as appropriate. Detailed search strategies for all databases are provided in Supplementary Table S2.
Study selection criteria
Types of studies
This meta-analysis included RCTs that evaluated the efficacy and safety of CNP-based therapies, such as vosoritide and navepegritide, in paediatric patients with achondroplasia. Eligible studies were required to employ a parallel-group randomised design comparing CNP-based interventions with either placebo or standard care. Studies that were non-randomised, observational, single-arm, preclinical or conducted in populations other than achondroplasia were excluded. Furthermore, review articles, conference abstracts lacking full data, case reports, case series, editorials, letters and methodological studies were not included.
Types of participants
This review included paediatric participants with achondroplasia who were enrolled in RCTs assessing CNP-based therapies. In the included studies, participants were typically children with genetically or clinically confirmed achondroplasia who remained in the active growth phase, characterised by open growth plates and baseline characteristics suitable for longitudinal assessment of growth outcomes. Both male and female participants were eligible for inclusion. At the trial level, eligibility criteria generally required a stable clinical condition and suitability for repeated growth and safety assessments during follow-up. Common exclusion criteria across studies were prior or recent exposure to therapies that could significantly affect growth, recent limb-lengthening procedures and clinically significant medical conditions that could interfere with study participation, outcome assessment or treatment safety.
Types of interventions
The intervention group received CNP-based therapies, including vosoritide and navepegritide, while the comparator group received a placebo.
Outcome measures
Primary outcome
The primary outcome was the least squares mean (LSM) difference in AGV cm/year at 52 weeks between CNP analogue therapy and placebo.
Secondary outcomes
The secondary outcomes were as follows:
The LSM difference in height Z-score (Centers for Disease Control and Prevention [CDC]-specific) at 52 weeks between the intervention and placebo groups
The LSM difference in upper-to-lower body segment ratio at 52 weeks between the intervention and placebo groups
-
Safety outcomes: These included the risk ratio (RR) of
Any adverse events (AE)
Serious AEs (SAE)
Injection-site reactions between the intervention and placebo groups.
Selection of studies
The selection of relevant studies was made in a stepwise manner. The titles, abstracts and keywords of every reference that was retrieved were first independently screened by three review reviewers. After obtaining and evaluating the full texts of a few chosen research, the authors included the studies that satisfied the selection criteria in the meta-analyses. Any disagreements among the authors were discussed with the fourth author, and the reasons for elimination were documented.
Data extraction and management
Three reviewers independently extracted data using a standardised form, following the Cochrane Handbook’s methodological recommendations.[18] Disagreements were resolved through discussion and consensus. For each included study, the following information was extracted: First author, year of publication, study design, participant characteristics (including age and sex distribution), diagnostic criteria, intervention details (type of CNP analogue, dosing regimen and number of participants), comparator details (placebo and number of participants), duration of follow-up and reported outcomes. For efficacy outcomes, LSM differences with corresponding 95% confidence intervals (CI) were directly extracted from the individual trials, as all included studies reported adjusted treatment effects rather than raw change scores. Standard errors (SE) were derived from the reported CI using the formula: SE = (upper limit−lower limit)/ (2 × 1.96), consistent with Cochrane recommendations.[18] This method maintained alignment with the original trial analyses and avoided recalculation from individual arm-level data. The primary outcome AGV was extracted at 52 weeks as reported in the included studies. Height Z-scores were extracted as reported and were based on age- and sex-specific reference data from the CDC, enabling standardised comparison of height relative to reference populations. For safety outcomes, data on any AE, SAE and injection-site reactions were extracted. Injection-site reactions were specifically included due to their consistent reporting and clinical relevance across all included trials. For each safety outcome, event counts and total participants in each group were recorded for quantitative synthesis. All extracted data were cross-verified for accuracy before analysis, and the final dataset was prepared for meta-analysis using predefined formats.
Statistical analysis
All statistical analyses were conducted using R statistical software (version 4.5.2). For continuous outcomes, such as AGV, height Z-score and upper-to-lower body segment ratio, treatment effects were summarised as mean differences (MD) with corresponding 95% CI. Pooled estimates were calculated using an inverse-variance random-effects model. Due to the limited number of included studies, random-effects meta-analyses were performed using the Hartung–Knapp–Sidik– Jonkman (HKSJ) method, which yields more robust and reliable CI estimation in meta-analyses with few studies.[19] For dichotomous safety outcomes, including any AE, SAE and injection-site reactions, treatment effects were expressed as RR with corresponding 95% CI. Results were pooled using random-effects models. Statistical heterogeneity was assessed using Cochran’s Q test, with a p < 0.10 considered indicative of significant heterogeneity and quantified using the I2 statistic. Sensitivity analyses were conducted to evaluate the robustness of the findings by excluding studies with differing baseline characteristics, particularly those including younger age groups, to assess the influence of population variability on the pooled estimates. In addition, an exploratory frequentist network meta-analysis (NMA) was conducted to assess the comparative efficacy of the included interventions. The resulting network exhibited a star-shaped geometry with no closed loops; therefore, formal inconsistency testing was not applicable. The risk of bias in the included RCTs was independently assessed by two reviewers using the Cochrane Risk of Bias 2 (RoB 2) tool, which evaluates bias in randomisation, deviations from intended interventions, missing outcome data, outcome measurement and selection of reported results.[20] Any disagreements were resolved through discussion. Publication bias was not formally assessed because the small number of included studies (n = 4) limited the reliability of funnel plot asymmetry and related statistical tests.
Assessment of certainty of the evidence
The ‘summary of findings’ table was created using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group guidelines and standard Cochrane methodology, considering each outcome’s certainty of evidence as well as the risk of bias, consistency, imprecision, indirectness, publication bias, large effect size, plausible confounding and dose-response gradient seen in the included studies.[21]
RESULTS
Search results
Figure 1[14,15,22,23] presents the study selection process using the PRISMA flow diagram. In total, 164 records were identified through electronic database and registry searches, including PubMed (n = 47), Embase (n = 56), Cochrane Central (n = 44) and clinical trial registers (n = 17). After removing 25 duplicate records, 139 studies remained for title and abstract screening. Of these, 120 records were excluded based on predefined eligibility criteria. Nineteen full-text articles were retrieved and assessed for eligibility. Fifteen studies were excluded for the following reasons: Inadequate data (n = 3), single-arm study design (n = 2), different population or intervention (n = 8) and abstract-only reports (n = 2). Four RCTs met the inclusion criteria and were included in the final systematic review and meta-analysis.

Study characteristics
Table 1 presents the main characteristics of four randomised, placebo-controlled trials that collectively enrolled 298 paediatric participants with achondroplasia. These studies were conducted across North America, Europe and the Asia-Pacific region and evaluated CNP-based therapies administered as subcutaneous injections compared with placebo. The phase 3 trial by Savarirayan et al. (2020) reported significant improvements in AGV and height Z-score with vosoritide compared with placebo, while no meaningful change in body proportionality was observed.[22] The phase 2 trial by Savarirayan et al. (2023) demonstrated a dose-dependent increase in AGV with navepegritide, with the highest dose showing a statistically significant benefit over placebo.[15] Similarly, Savarirayan et al. (2024) observed improvements in growth velocity and height Z-score with vosoritide treatment, although changes in the upper-to-lower body segment ratio were minimal.[23] The most recent phase 2b trial by Savarirayan et al. (2026) showed significant improvements in AGV and height Z-score with navepegritide, along with additional benefits in skeletal alignment parameters.[14] Across all studies, the treatment duration was 52 weeks, and safety profiles were generally favourable, with most AE being mild and manageable. Collectively, these findings demonstrate consistent improvements in growth-related outcomes with CNP-based therapies compared with placebo. Baseline demographic and clinical characteristics of the included studies are provided in Table 2.
| Sr. No | Author, Year, Place | Study design | Participants | Arm | Number of participants | Duration | Outcome | Remarks |
|---|---|---|---|---|---|---|---|---|
| 1 | Savarirayan et al.[22] 2020 (Australia, Germany, Japan, Spain, Turkey, USA, UK) | RCT phase 3 trial | Children aged 5 to less than 18 years with a genetically confirmed diagnosis of achondroplasia, who were ambulatory and had completed at least 6 months of a baseline observational growth study to establish annualized growth velocity, were included. | 1) Vosoritide 15 mcg/Kg once daily Subcutaneous 2) Placebo |
60 61 |
52 weeks | 1) Change from baseline in annualised growth velocity (primary) 2) Height Z-score (secondary) 3) Upper/lower body segment ratio 4) Safety outcomes |
Vosoritide treatment resulted in a statistically significant increase in annualized growth velocity compared with placebo at 52 weeks. Significant improvements were also observed in height Z-score, while no meaningful change was noted in upper-to-lower body segment ratio. |
| 2 | Savarirayan et al.[15] 2023 (Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal, and the United States) | RCT Phase 2 trial | Children with achondroplasia aged 2 to 10 years with genetically confirmed diagnosis, open growth plates, and impaired linear growth were enrolled. Participants were required to have completed a baseline growth assessment period to establish annualized growth velocity and be otherwise clinically stable. | 1) Navepegritide 100 mcg/Kg once weekly Subcutaneous 2) Placebo |
11 15 |
52 weeks | 1) Change in annualised growth velocity (primary) 2) Height SDS (secondary) 3) Safety (adverse events, hypotension, immunogenicity) |
Treatment with TransCon CNP (navepegritide) demonstrated a dose-dependent increase in annualized growth velocity, with the highest dose (100 µg/kg/ week) showing a statistically significant improvement compared with placebo. |
| 3 | Savarirayan et al.[23] 2024 (Europe, North America, Australia) | RCT Phase 2 trial | Children less than 5 years with genetically confirmed achondroplasia, open growth plates, and impaired linear growth were enrolled. Participants were required to be ambulatory and have stable clinical status were enrolled in this trial. | 1) Vosoritide 15 mcg/Kg once daily Subcutaneous 2) Placebo |
32 32 |
52 weeks | 1) Change from baseline in annualised growth velocity (primary) 2) Height Z-score (secondary) 3) Upper/lower body segment ratio 4) Safety outcomes |
Vosoritide demonstrated a dose-dependent increase in annualized growth velocity, with the highest dose (15 mcg/ kg/day) showing the greatest improvement compared with placebo. Improvements in height Z-score were also observed, while body proportionality remained largely unchanged. |
| 4 | Savarirayan et al.[14] 2026 (Australia, Canada, Denmark, Ireland, New Zealand, Spain, and the US) | RCT Phase 2b trial | Children aged 2 to 11 years with genetically confirmed achondroplasia, naïve to treatment with growth-promoting agents, and with height recorded at least 6 months before randomization were eligible. Participants had to be able to stand without assistance and have a caregiver willing and able to administer subcutaneous injections were enrolled in this trial. | 1) Navepegritide 100 mcg/Kg once weekly Subcutaneous 2) Placebo |
60 27 |
52 weeks | 1) Change from baseline in annualised growth velocity (primary) 2) Height Z-score (secondary) 3) Exploratory outcomes included upper-to-lower body segment ratio, fibula-to-tibia length ratio, tibial-femoral angle, mechanical axis deviation, and additional skeletal alignment measures. Safety outcomes |
Navepegritide significantly improved annualized growth velocity versus placebo at 52 weeks, with an LS mean treatment difference of 1.49 cm/year. It also significantly improved achondroplasia-specific height z score and showed additional benefits beyond growth, including improvement in lower limb alignment measures such as tibial-femoral angle, mechanical axis deviation, and fibula-to-tibia length ratio. |
RCT: Randomized controlled trial; SDS: Standard deviation score; CNP: C-type natriuretic peptide
| Study | Arm | Age, years Mean (SD) | Sex Female, n (%) | Height z score (CDC- based), Mean (SD) | AGV (cm/years), Mean (SD) |
|---|---|---|---|---|---|
| Savarirayan et al.[22] 2020 | Vosoritide | 8.35 (2.43) | 29 (48%) | -5.13 (1.11) | 4.26 (1.53) |
| Placebo | 9.06 (2.47) | 28 (46%) | -5.14 (1.07) | 4.06 (1.2) | |
| Savarirayan et al.[15] 2023 | Navepegritide | 5.8 (2.6) | 6 (55%) | -4.92 (0.83) | NA |
| Placebo | 5.9 (3.1) | 5 (33%) | -4.85 (0.96) | NA | |
| Savarirayan et al.[23] 2024 | Vosoritide | 2.03 (1.4) | 15 (47%) | -3.79 (0.97) | 11.06 (7.57) |
| Placebo | 2.31 (1.6) | 19 (59%) | -4.28 (1.48) | 9.6 (7.74) | |
| Savarirayan et al.[14] 2026 | Navepegritide | 5.6 (2.6) | 14 (51.9%) | -4.9 (1) | 4 (1.9) |
| Placebo | 6 (2.7) | 13 (48.1%) | -5.21 (0.9) | 3.8 (2) |
AGV: Annualized growth velocity; SD: Standard deviation; CDC: Centers for Disease Control and Prevention; NA: Not available
Primary outcome
Data from four RCTs were analysed to assess AGV. Heterogeneity among the included studies was low to moderate (I2 = 26.1%, p = 0.255), indicating that variability across studies was not statistically significant. Nevertheless, a random-effects model with HKSJ adjustment was employed due to the small number of studies and potential clinical differences across trials. The forest plot indicated that effect estimates from all individual studies consistently favoured CNP-based therapy over placebo. Pooled analysis demonstrated a statistically significant improvement in AGV, with an MD of 1.39 cm/year (95% CI: 0.89–1.90). The prediction interval ranged from 0.77 to 2.02 cm/year, suggesting that the true treatment effect in a future study is likely to favour the intervention, although some variability may occur [Figure 2].[14,15,22,23]

Secondary outcome
Height Z-score (CDC-specific)
Data from three RCTs were included to assess height Z-score, while one study was excluded due to the absence of CDC- based height Z-score reporting. The included studies showed no significant heterogeneity (I2 = 0.0%, p = 0.949), suggesting consistent results across trials. A random-effects model with HKSJ adjustment was applied. The forest plot indicated that all individual studies favoured CNP-based therapy over placebo. Pooled analysis revealed a significant improvement in height Z-score, with an MD of 0.28 (95% CI: 0.24–0.33). The prediction interval ranged from approximately 0.10 to 0.47, suggesting that although the treatment effect favours the intervention, some variability in effect size may occur in future studies [Figure 3].[14,22,23]

Upper-to-lower body segment ratio
Data from four RCTs were analysed to evaluate the upper-to-lower body segment ratio. Heterogeneity among the included studies was not significant (I2 = 0.0%, p = 0.744), indicating no observed variability across trials. A random-effects model with HKSJ adjustment was applied. The forest plot indicated that individual study estimates centred around the null effect, with no consistent direction favouring either group. The pooled analysis demonstrated no significant difference between CNP-based therapy and placebo, with an MD of −0.02 (95% CI: −0.05–0.01). The prediction interval, ranging from approximately −0.06–0.02, suggests that future studies are also unlikely to demonstrate a meaningful effect [Figure 4].[14,15,22,23]

Safety assessment
Data from four RCTs were analysed to evaluate any AE. Heterogeneity among studies was not significant (I2 = 0.0%, p = 0.833), supporting consistency across trials. A random-effects model with HKSJ adjustment was utilised. The pooled analysis indicated no significant difference in the risk of any AE between CNP-based therapy and placebo, with a pooled RR of 0.99 (95% CI: 0.96–1.02) [Figure 5a].[14,15,22,23]

For SAE, data from three trials were included. The heterogeneity was not significant (I2 = 0.0%, p = 0.883). The pooled estimate showed no statistically significant difference between groups, with a pooled RR of 0.56 (95% CI: 0.30– 1.06) [Figure 5b].[14,22,23]
Analysis of injection-site reactions from four trials showed a significantly higher risk associated with CNP-based therapy compared to placebo. The heterogeneity was not significant (I2 = 0.0%, p = 0.771). The pooled RR was 1.64 (95% CI: 1.29–2.09), indicating a statistically significant increase in injection-site reactions in the intervention group [Figure 5c].[14,15,22,23] Subgroup analysis showed a significant increase in injection-site reactions with vosoritide (RR = 1.67, 95% CI: 1.30–2.15), while navepegritide did not demonstrate a statistically significant difference (RR = 1.32, 95% CI: 0.53–3.26). The test for subgroup differences was not statistically significant (p = 0.618) [Figure S1].
Supplementary Table S3 summarises individual AEs. The most frequently reported events were pyrexia, nasopharyngitis, upper respiratory tract infections, vomiting and headache, which occurred at similar rates in both groups. Less frequent events included arthralgia, otitis media, cough, diarrhoea and hypotension. Overall, AEs were predominantly mild and manageable, with no consistent pattern of serious safety concerns identified across the included studies.
Exploratory NMA of AGV
An exploratory NMA was conducted to assess the comparative effects of navepegritide and vosoritide on AGV. The network exhibited a star-shaped structure, with placebo as the common comparator and no direct head-to-head evidence between the active treatments [Figure S2]. Both navepegritide and vosoritide demonstrated significant improvements in AGV compared with placebo [Figure S3]. The exploratory indirect comparison through the common placebo comparator did not demonstrate a statistically significant difference between navepegritide and vosoritide (MD = 0.06 cm/year, 95% CI: −0.82–0.95) [Supplementary Table S4]. Given the absence of direct head-to-head evidence and the limited number of trials, this finding should not be interpreted as evidence of equivalence or comparable efficacy between the two agents.
Sensitivity analysis
A leave-one-out sensitivity analysis was conducted to evaluate the robustness of the primary outcome. The influence of a study involving a younger population (under 5 years) on the pooled estimate was specifically assessed. Sequential exclusion of individual studies did not substantially change the direction or statistical significance of the pooled effect; all estimates continued to favour CNP-based therapy. Notably, heterogeneity decreased when the study with younger participants was excluded, as indicated by I2 decreasing to 0%, suggesting this study was a potential source of between-study variability [Figure S4]. These findings demonstrate that the observed treatment effect is robust and not dependent on any single study, although differences in study populations contributed to heterogeneity.
Certainty of evidence
The certainty of evidence for all outcomes was evaluated using the GRADE approach [Table 3]. Certainty was rated as high for the primary outcome and for height Z-score, as no serious concerns were identified regarding risk of bias, inconsistency, indirectness or imprecision. Effect estimates for these outcomes were consistent across studies and directly addressed the review question. The certainty of evidence for the upper-to-lower body segment ratio was rated as moderate, with a downgrade for imprecision because the CI crossed the null value. Similarly, certainty for any AE and SAE was rated as moderate, primarily due to imprecision in the effect estimates. In contrast, the certainty of evidence for injection-site reactions was rated as high, supported by precise effect estimates, consistent findings across studies and the absence of heterogeneity.
| Certainty assessment | ||||||
| Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations |
| Annualized growth velocity (AGV) cm/year | ||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None |
| Height Z-score (CDC-specific) | ||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None |
| Upper-to-lower body segment ratio | ||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Serious | None |
| Any AE | ||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Serious | None |
| SAE | ||||||
| 3 | Randomised trials | Not serious | Not serious | Not serious | Serious | None |
| Injection site reaction | ||||||
| 4 | Randomised trials | Not serious | Not serious | Not serious | Not serious | None |
| No of studies | No of patients | Effect | Certainty | Importance | ||
| CNP analogs | Placebo | Relative (95% CI) | Absolute (95% CI) | |||
| Annualized growth velocity (AGV) cm/year | ||||||
| 4 | 160 | 135 | - | MD 1.39 cm/year higher (0.89 higher to 1.9 higher) | ⨁⨁⨁⨁ High |
Critical |
| Height Z-score (CDC-specific) | ||||||
| 4 | 160 | 135 | - | MD 0.28 higher (0.26 higher to 0.29 higher) |
⨁⨁⨁⨁ High |
Critical |
| Upper-to-lower body segment ratio | ||||||
| 4 | 160 | 135 | - | MD 0.02 lower (0.05 lower to 0.01 higher) |
⨁⨁⨁◯ Moderate |
Critical |
| Any AE | ||||||
| 4 | 153/160 (95.6%) | 132/135 (97.8%) | RR 0.99 (0.96 to 1.02) |
10 fewer per 1,000 (from 39 fewer to 20 more) |
⨁⨁⨁◯ Moderate |
Critical |
| SAE | ||||||
| 3 | 9/149 (6.0%) | 13/120 (10.8%) | RR 0.56 (0.30 to 1.06) |
48 fewer per 1,000 (from 76 fewer to 7 more) |
⨁⨁⨁◯ Moderate |
Critical |
| Injection site reaction | ||||||
| 4 | 83/160 (51.9%) | 48/135 (35.6%) | RR 1.64 (1.29 to 2.09) |
228 more per 1,000 (from 103 more to 388 more) |
⨁⨁⨁⨁ High |
Critical |
CI: Confidence interval; MD: Mean difference; RR: Risk ratio; AE: Adverse events; SAE: Serious adverse events; CNP: C-type natriuretic peptide; CDC: Centers for Disease Control and Prevention ; GRADE certainty of evidence: ⨁ indicates a level of certainty achieved and ◯ indicates a level not achieved; ⨁⨁⨁⨁, high; ⨁⨁⨁◯, moderate; ⨁⨁◯◯, low; ⨁◯◯◯, very low.
Risk of bias in included studies
Figure 6 presents the risk of bias assessment for the included studies, conducted using the Cochrane RoB 2 tool. Two studies (Savarirayan et al., 2020; Savarirayan et al., 2026) were identified as having some concerns, primarily in the domain of selection of the reported results (D5) and were therefore assigned an overall judgement of ‘some concerns’.[14,22] The remaining studies (Savarirayan et al., 2023; Savarirayan et al., 2024) were judged to have a low risk of bias across all domains. In summary, the included trials demonstrated high methodological quality, with no studies assessed as having a high risk of bia s.[15,23]

DISCUSSION
This systematic review and meta-analysis of RCTs found that CNP-based therapies significantly improved AGV compared with placebo, with consistent results across studies. A significant increase in height Z-score (CDC-specific) was also observed, indicating enhanced standardised growth relative to age- and sex-matched populations. However, no significant difference was detected in the upper-to-lower body segment ratio, suggesting that improvements in linear growth may not be accompanied by changes in body proportionality over the study period. These findings were consistent across trials with low to moderate heterogeneity, and sensitivity analyses confirmed the robustness of the treatment effects, indicating that no single study unduly influenced the results. Collectively, these results support the efficacy of CNP-based therapies in improving growth outcomes in children with achondroplasia.
CNP-based therapies were generally well tolerated, with no significant difference in the risk of any AE or SAE compared with placebo. These results indicate that treatment with CNP analogues does not increase the risk of overall or serious toxicity in the studied population. However, a significantly higher incidence of injection-site reactions occurred with CNP-based therapy, which is consistent with the subcutaneous route of administration and was predominantly mild. Subgroup analysis showed that the increased risk of injection-site reactions was primarily associated with vosoritide, while navepegritide did not show a statistically significant increase. This variation may be attributable to differences in dosing frequency and pharmacokinetic profiles between the two agents. However, the test for subgroup differences was not statistically significant, suggesting insufficient evidence to confirm a true difference between interventions. These findings should be interpreted with caution due to the limited number of studies and the lack of direct head-to-head comparisons.
In addition, an exploratory NMA was performed to compare the relative efficacy of CNP-based therapies. The network exhibited a star-shaped structure with placebo as the common comparator, and no direct head-to-head comparisons between active interventions were available. Both vosoritide and navepegritide were associated with improvements in AGV compared with placebo; however, the indirect comparison did not demonstrate a statistically significant difference between the two agents and should be interpreted cautiously given the exploratory nature of the analysis. As no closed loops were present, formal inconsistency assessment was not applicable. The methodological quality of the included studies was high, with most trials assessed as having a low risk of bias and only some concerns regarding selective reporting. The certainty of evidence, evaluated using the GRADE approach, was rated as high for the primary and key secondary outcomes, reflecting consistent and precise effect estimates across studies. Although the total sample size was relatively small, this is expected given the rarity of achondroplasia, and the included trials represent the best available randomised evidence.
The findings of this analysis should be interpreted within the context of current clinical recommendations.[24] Recent international consensus on achondroplasia emphasises the need for multidisciplinary management and highlights emerging pharmacological therapies to improve growth outcomes. Consistent with these recommendations, both vosoritide and navepegritide demonstrated beneficial effects on growth velocity compared with placebo in this analysis. However, the consensus also indicates that management should address long-term clinical outcomes, functional status and complication monitoring in addition to growth. Thus, while improvements in growth parameters support the therapeutic role of CNP analogues, their overall clinical impact must be evaluated within a comprehensive, multidisciplinary care framework.
The observed improvement in AGV with CNP-based therapies is clinically relevant, as impaired linear growth is a central manifestation of achondroplasia and sustained increases in growth velocity may contribute to improved height attainment during childhood. However, the clinical implications of short-term improvements in AGV extend beyond stature and remain incompletely established. Current randomised evidence does not yet determine whether these gains translate into meaningful improvements in final adult height, body proportionality, physical function, quality of life or the burden of achondroplasia-related complications. Furthermore, continued surveillance is required to characterise long-term safety, particularly with prolonged treatment throughout childhood. Long-term follow-up studies incorporating growth, functional, patient-reported and safety outcomes are therefore essential to establish the overall clinical benefit of CNP-based therapy.
Consistent with existing literature, a recent systematic review and meta-analysis of real-world vosoritide use reported significant improvements in AGV and height Z-score, along with a favourable safety profile predominantly characterised by mild injection-site reactions.[25] However, that analysis was primarily based on observational data without a placebo comparator, limiting the ability to establish causal treatment effects and increasing susceptibility to confounding. In contrast, the present study included only randomised placebo-controlled trials, providing a higher level of evidence for efficacy and safety. Importantly, although vosoritide and navepegritide share a common CNP-mediated mechanism of action, differences in pharmacokinetic profiles (daily versus long-acting formulations) may influence clinical outcomes and tolerability. By incorporating multiple CNP analogues and conducting an exploratory NMA, this study enables indirect comparative assessment between agents, which was not addressed in previous analyses. Therefore, our findings extend the current evidence base by offering a more rigorous and comparative evaluation of available CNP-based therapies in achondroplasia.
Beyond CNP analogues, additional emerging therapies targeting alternative pathways are under investigation for the treatment of achondroplasia. Infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, has demonstrated improvements in growth velocity in phase 2 studies;[26] however, the absence of placebo-controlled trials restricts its inclusion in comparative analyses. Similarly, meclizine has been evaluated as a potential therapeutic agent, with early-phase studies indicating modest effects on growth parameters, particularly arm span, but without significant improvement in height velocity.[27] These results underscore the expanding therapeutic landscape, yet robust RCTs remain necessary to determine comparative efficacy.
The present study has several strengths. It included only RCTs, allowing for robust estimation of treatment effects. The analysis incorporated multiple CNP analogues, enabling a broader evaluation of available therapies. Standardised outcome measures and consistent follow-up durations across studies enhanced comparability. A random-effects meta-analysis using the HKSJ method was applied, yielding more reliable CI estimates given the small number of studies. Importantly, to the best of our knowledge, this is the first systematic review and meta-analysis to comprehensively evaluate the efficacy and safety of CNP analogues in achondroplasia, including an exploratory NMA to assess indirect comparisons between interventions. The certainty of evidence was rated as high for key outcomes, supporting the robustness of the findings.
This study has several limitations. First, the number of included RCTs and the total sample size were relatively small, which may limit the precision of effect estimates. This limitation reflects the rarity of achondroplasia and the scarcity of available randomised evidence. Second, one study included participants younger than 5 years, potentially contributing to clinical heterogeneity across trials. Nevertheless, sensitivity analyses confirmed the robustness of the findings. Third, publication bias could not be formally assessed because of the limited number of included studies; therefore, the possibility of publication bias cannot be excluded. Fourth, meta-regression analysis could not be conducted because of variations in baseline characteristics across studies. However, most trials reported outcomes as LSM differences, which partially accounts for baseline variability. Finally, although the certainty of evidence was rated as high for key outcomes, this should be interpreted in the context of the limited number of studies available in this rare disease setting.
Future research should focus on large, well-designed RCTs with longer follow-up durations to better evaluate the long-term efficacy, safety and impact on body proportionality and functional outcomes. Direct head-to-head comparative studies between different CNP analogues are needed to establish relative efficacy. In addition, studies exploring combination or alternative therapeutic approaches targeting different pathways, such as FGFR inhibition, may further optimise treatment strategies for achondroplasia.
CONCLUSION
In conclusion, CNP-based therapies significantly improve growth outcomes, including AGV and height Z-score, in children with achondroplasia, with an acceptable safety profile. No significant differences were observed between available agents in indirect comparisons. These findings support the role of CNP analogues as an effective therapeutic option; however, their use should be considered within a comprehensive multidisciplinary care approach addressing long-term clinical outcomes, functional status and associated complications. Further long-term and head-to-head studies are required to optimise treatment strategies.
Ethical approval:
Institutional Review Board approval is not required as this study is a systematic review and meta-analysis of previously published studies and did not involve direct participation of human subjects or collection of individual patient data.
Declaration of patient consent:
Patient’s consent is not required as there are no patients in this study.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology . During the preparation of this work, the author(s) used Grammarly to improve the English language and readability of the manuscript. After using this tool, the author(s) reviewed and edited the content as needed and take full responsibility for the content of the publication.
Financial support and sponsorship: Nil.
References
- Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78:335-42.
- [CrossRef] [PubMed] [Google Scholar]
- Achondroplasia: Development, pathogenesis, and therapy. Dev Dyn. 2017;246:291-309.
- [CrossRef] [PubMed] [Google Scholar]
- Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Bone. 2021;146:115872.
- [CrossRef] [PubMed] [Google Scholar]
- Achondroplasia: A comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1.
- [CrossRef] [PubMed] [Google Scholar]
- International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18:173-89.
- [CrossRef] [PubMed] [Google Scholar]
- Health supervision for people with achondroplasia. Pediatrics. 2020;145:e20201010.
- [CrossRef] [PubMed] [Google Scholar]
- Growth hormone therapy in achondroplasia. Horm Res. 2000;53(Suppl 3):53-6.
- [CrossRef] [PubMed] [Google Scholar]
- Limb lengthening in patients with achondroplasia. Yonsei Med J. 2015;56:1656-62.
- [CrossRef] [PubMed] [Google Scholar]
- Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004;10:80-6.
- [CrossRef] [PubMed] [Google Scholar]
- Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108-14.
- [CrossRef] [PubMed] [Google Scholar]
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021;23:2443-7.
- [CrossRef] [PubMed] [Google Scholar]
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med. 2025;6:100566.
- [CrossRef] [PubMed] [Google Scholar]
- Once-weekly navepegritide in children with achondroplasia: The APPROACH randomized clinical trial. JAMA Pediatr. 2026;180:18-25.
- [CrossRef] [PubMed] [Google Scholar]
- Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): A phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial. EClinicalMedicine. 2023;65:102258.
- [CrossRef] [PubMed] [Google Scholar]
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ. 2015;350:g7647.
- [CrossRef] [PubMed] [Google Scholar]
- Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6:e1000097.
- [CrossRef] [PubMed] [Google Scholar]
- Cochrane Handbook for Systematic Reviews of Interventions In: Ver. 6.4. London: Cochrane Collaboration; 2023.
- [Google Scholar]
- The hartung-knapp-sidik-jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard dersimonian-laird method. BMC Med Res Methodol. 2014;14:25.
- [CrossRef] [PubMed] [Google Scholar]
- The cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: A perspective on the pros and cons. Health Sci Rep. 2024;7:e2165.
- [CrossRef] [PubMed] [Google Scholar]
- GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94.
- [CrossRef] [PubMed] [Google Scholar]
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: A randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684-92.
- [CrossRef] [PubMed] [Google Scholar]
- Vosoritide therapy in children with achondroplasia aged 3-59 months: A multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024;8:40-50.
- [CrossRef] [PubMed] [Google Scholar]
- An overview of the international consensus statement on achondroplasia. Orphanet J Rare Dis. 2026;21:34.
- [CrossRef] [PubMed] [Google Scholar]
- Real-world outcomes of vosoritide in achondroplasia: A systematic review and meta-analysis of multinational clinical evidence. Genet Med. 2026;28:101670.
- [CrossRef] [PubMed] [Google Scholar]
- Oral infigratinib therapy in children with achondroplasia. N Engl J Med. 2025;392:865-74.
- [CrossRef] [PubMed] [Google Scholar]
- Efficacy and safety of oral meclizine for growth promotion in children with achondroplasia: A phase 2 clinical trial. Calcif Tissue Int. 2025;116:143.
- [CrossRef] [PubMed] [Google Scholar]
